Alpha thalassemia/mental retardation X-linked (ATRX) protein expression in human pituitary neuroendocrine tumours and its reported correlation to prognosis and clinical outcomes: A systematic review.

Edward Wang[1*], Fabio Rotondo[2], Michael D. Cusimano[1,3]

[1]Department of Surgery, Division of Neurosurgery, St. Michael's Hospital; Injury Prevention Research Office, Li Ka Shing Knowledge Institute, Keenan Research Centre; University of Toronto; Toronto, Canada

[2]Department of Laboratory Medicine, Division of Pathology, Unity Health Toronto- St. Michael's Hospital, Toronto, ON, Canada

[3]Dalla Lana School of Public Health, University of Toronto, Toronto, Canada

*Corresponding author

Email: ewang242@uwo.ca (EW)

Abstract

Mutations in Alpha thalassemia/mental retardation X-linked (ATRX) have been implicated in several cancers, including gliomas, sarcomas, neuroendocrine tumors, and other mesenchymal malignancies. ATRX loss contributes to oncogenesis, accelerates tumor growth, and reduces survival by disrupting epigenetic and telomere mechanisms. Additionally, ATRX loss can increase tumor sensitivity to treatment therapies. While research has explored ATRX expression in many cancers, data on its relationship to prognosis in pituitary neuroendocrine tumors (PitNETs) remain inconsistent. This systematic review aims to summarize all available studies on ATRX mutations and expression in PitNETs. A systematic search of PubMed, Scopus, and EMBASE databases was conducted to identify publications between 2014 and 2025 that investigated ATRX mutations or expression in PitNETs, following PRISMA 2020 guidelines. Of 32 identified studies, ten met the inclusion criteria, covering a total of 513 PitNETs. Only 20 tumors (3.9%) showed a loss of ATRX expression. Among these, 60% exhibited corticotropic pathology, while 20% displayed lactotrophic pathology. A small subset of tumors (30%) was classified as pituitary carcinomas with aggressive and proliferative characteristics. Additionally, 10% demonstrated the alternative lengthening of telomeres (ALT) phenotype, 50% had concurrent TP53 mutations, and 25% had elevated Ki-67 indices, indicating a higher proliferative index. Although ATRX mutations are rare in PitNETs, tumors with ATRX loss tend to be more aggressive and exhibit proliferative and transformative properties. Due to the limited number of cases, further studies with larger, prospective cohorts are needed to better understand the role of ATRX loss in PitNET progression and aggressiveness.

43 # Introduction

44 Alpha thalassemia/mental retardation X-linked (ATRX) is an ATP-dependent chromatin
45 remodelling protein within the switch/sucrose nonfermentable (SWI/SNF) family of chromatin
46 remodelling proteins. ATRX features two conserved domains: an ATRX-DNMT3-DNMT3L (ADD)
47 domain at the N-terminus and a SNF2 ATPase/helicase domain at the C-terminus. The ADD
48 domain contains critical structures for chromatin localization and binding, housing a GATA-like
49 domain and a PHD-like domain [1]. In neuronal cells, a MECP2 binding domain found within the
50 ATPase domain drives recruitment of ATRX to heterochromatin targets. The ATP-dependent
51 helicase domain is characteristic of other SNF chromatin remodeling proteins and enables
52 functional activity of ATRX (Fig 1) [2]. Germline mutations in these domains are associated with
53 the development of ATR-X syndrome, from which the protein derives its name [1].

54

55 **Fig 1. Schematic representation of the ATRX protein showing its major functional domains.**
56 The N-terminal ADD domain, containing GATA-like and PHD-like domains, mediates chromatin
57 localization and binding [1,2]. A neuronal MECP2 (nMECP2) binding domain provides an
58 alternative route for ATRX recruitment to chromatin targets [2]. The unstructured central region
59 harbors "SDT-like" domains, which modulate MRN activity, and a DAXX-binding domain
60 essential for DAXX-mediated heterochromatin regulation [3]. Towards the C-terminus, the SNF2
61 ATPase/helicase domain promotes chromatin remodeling. Additional features include an EZH2
62 domain, which supports PRC2-associated histone methylation, and an HP1α binding domain,
63 facilitating heterochromatin recognition and PML nuclear body interactions [1,2].

64 ATRX also contains three other domains critical to its function: (1) an enhancer of zeste
65 homolog 2 (EZH2) binding domain, which includes an HP1α binding domain, (2) several central
66 "SDT-like" domains within the unstructured central region of the protein, and (3) a death
67 domain-associated protein (DAXX) binding domain. The ATRX/EZH2 complex is recruited to a
68 larger polycomb repressive complex 2 (PRC2) to modulate trimethylation of H3K27 (H3K27me3)
69 , silencing genes surrounding the modified histone (Fig 2). This function is utilized in
70 transcription regulation as early as embryonic development, where ATRX is involved in X-
71 chromosome inactivation [1,2]. The ATRX/DAXX complex localizes to promyelocytic leukemia
72 nuclear bodies (PML-NBs), subnuclear multiprotein structures involved in gene expression,
73 chromatin regulation, and DNA repair [2,4,5]. ATRX/DAXX modulates the deposition of histone
74 H3.3 at guanine-rich heterochromatin regions with highly repetitive elements, including
75 telomeres and pericentromeric regions [1,5–7]. HP1α facilitates ATRX/DAXX preferential
76 recognition and binding to H3K9me3, facilitating histone H3.3 deposition and maintenance of
77 heterochromatin integrity [5,8,9]. The SDT-like domains consist of spaced repeats of Ser-X-Thr
78 motifs, where X is either Asp or Glu. When phosphorylated, these SDT-like domains enable ATRX
79 to interact with the MRE11-RAD50-NBS1 (MRN) complex, a necessary interaction for ATRX-
80 mediated DNA damage response (DDR) for double-stranded breaks (DSBs) and stalled
81 replication forks [2,3]. ATRX sequesters MRN from telomeres, preventing aberrant DDR
82 activation and preserving telomere stability (Fig 2).
83
84 **Fig 2. Overview of known molecular pathways of ATRX.** The ATRX/DAXX complex localizes to
85 PML nuclear bodies, where it is recruited to telomeres, pericentromeric heterochromatin, and

86 other DNA repeat regions. This recruitment is facilitated by HP1α, which recognizes H3K9me3
87 marks, allowing ATRX/DAXX to deposit histone H3.3 and maintain heterochromatin integrity
88 [1,2,5,8,9]. ATRX also forms a complex with EZH2 and is incorporated into the larger PRC2
89 complex, interacting with Xist lncRNA to promote X chromosome inactivation during early
90 female embryonic development [1,2]. In addition, ATRX sequesters the MRN complex from
91 telomeric regions, preserving telomere stability [2]. Beyond its role in heterochromatin
92 maintenance, ATRX modulates replacement of histone macroH2A from gene loci, thereby
93 maintaining a euchromatic state at target genes, including those encoding α-globin and
94 tankyrase, and thus supporting their transcription. ATRX is also implicated in the DNA damage
95 response at stalled replication forks through multiple mechanisms. It indirectly reduces
96 telomere cohesion and telomere sister chromatid exchanges (T-SCEs) by regulating tankyrase,
97 which in turn decreases transcription of TERRA, a long noncoding RNA (lncRNA) originating
98 from telomeric DNA. Excess TERRA promotes secondary structures such as G-quadruplexes (G4)
99 and R-loops that can stall replication forks [2,10–15]. ATRX helps sequester TERRA and
100 participates in resolving these secondary structures, although its precise mechanism of action
101 remains to be fully elucidated. Influenced and adapted from [1,2]
102
103 Beyond its role in DNA repair and gene silencing, ATRX also facilitates transcription of
104 key genes, including α-globin, a protein essential for hemoglobin function, and tankyrase, a
105 group of enzymes belonging to the poly(ADP-ribose) polymerase (PARP) superfamily. Impaired
106 α-globin transcription is associated with presentation of α-thalassemia, and in germline
107 situations, ATR-X (Fig 3) [10–12]. Tankyrase inhibits telomere cohesion and recombination

108 between sister telomeres, which if allowed to progress, destabilize telomeres and promote
109 aberrant transcription. The resulting transcripts form the long noncoding RNA (lncRNA) TERRA,
110 which can hybridize to other genomic regions and induce the formation of G-quadruplexes (G4)
111 and R-loops (Fig 2). Impaired transcription of tankyrase may prevent proper resolution of these
112 secondary structures, leading to stalled replication forks error-prone DDR pathways [2,13–15].
113

114 **Fig 3. Summary of the effects of ATRX mutations on disease, tumors, and development.**
115 Mutations in conserved ATRX domains impair α-globin transcription, leading to α-thalassemia.
116 Germline mutations of these domains induce the development of ATR-X syndrome. Mutations
117 to ATRX in gliomas have been observed to inhibit production of DRG2 and RPRM, proteins
118 critical for regulation of the G2M checkpoint [2,16,17]. $IDH1^{R132H}$+ gliomas with ATRX mutations
119 exhibit BRD3/4-dependent immune escape, which involves elevated PD-L expression and
120 increased production of cytokines. including but not limited to CXCL, CSF2, IL-6, IL-8, and IL-33.
121 This culminates with increased recruitment of M2 macrophages and T-cell exhaustion,
122 facilitating immune escape [1,18,19]. ATRX loss increases dsRNA production, activating a
123 signaling cascade through RIG1, MDA-5, STAT1, and ISG15 that boosts type I interferon and
124 cytokine output, ultimately enhancing recruitment of CD3+ and CD4+ T cells and increasing
125 innate immunity sensitization [1,18]. Disruption of ATRX/EZH2 complex formation reduces
126 suppression of FADD production, allowing FADD-mediated PARP sequestration and heightening
127 sensitivity to temozolomide (TMZ) [2,20,21]. In PanNETs, ATRX-DAXX-MEN1 (A-D-M) mutations
128 hypermethylate CpG islands at PDX1 gene loci, compromising β-cell function [1,2,22]. Loss of
129 ATRX is also a common driver of the ALT (alternative lengthening of telomeres) phenotype,

130 which features APB (ALT-associated PML bodies) formation, increased telomeric sister
131 chromatid exchanges (T-SCEs), accumulation of extrachromosomal C-circles, and heightened
132 TERRA-induced G-quadruplex and R-loop formation [1,2,13–15]. Finally, ATRX dysfunction has
133 been proposed to influence early bone development by downregulating CART, thereby reducing
134 osteoclast activity and increasing trabecular bone formation [23]. Influenced and adapted from
135 [1,2].
136
137 ATRX also participates in the resolution of G4 and R-loop structures. Although the exact
138 mechanism of action is unclear, ATRX has been proposed to act directly or exert secondary
139 effects that facilitate homologous recombination (HR)-mediated resolution of secondary
140 structures. ATRX has also been proposed to inhibit the formation of secondary structures by
141 sequestering free TERRA [1,2,24,25]. When ATRX function is disrupted, its silencing activity is
142 lost, resulting in elevated EZH2 and MRN activity at target sites and reduced suppression of
143 ATRX/DAXX-regulated regions. This deregulation promotes aberrant transcription [8].
144 Examination of the genetic factors influencing tumour initiation and progression has
145 long been a central focus of oncology research (Table 1). Deleterious mutations disrupting ATRX
146 function are frequently observed among several tumour types (Fig 3). ATRX mutations have
147 been most frequently linked to the development of the alternative lengthening of telomeres
148 (ALT) pathway, a telomerase-independent mechanism that confers replicative immortality on
149 cancer cells [19]. Mutations affecting the DAXX and SDT-like domains promote the formation of
150 ALT-associated PML-NBs (APBs), characteristic of ALT-positive cells. Unlike PML-NBs, APBs
151 localize at normally silent repetitive regions, driving aberrant transcription of telomeric and

152 pericentric sequences normally silenced by ATRX. Consequently, telomere sister chromatid
153 exchanges (T-SCEs), extrachromosomal telomeric C-circles, and TERRA-driven G4 and R-loop
154 structures become more prevalent, increasing the frequency of stalled replication forks. Since
155 ATRX also participates in replication fork repair, ALT-positive cells exhibit higher rates of
156 replication fork collapse and greater reliance on non-homologous end-joining (NHEJ), elevating
157 mutation rates and genomic instability [1–3].

158 Loss of ATRX function correlates with increased ALT activation in melanomas and
159 sarcomas, conferring heightened proliferative capacity and poorer disease-free survival [1,26–
160 28]. Somatic ATRX mutations are also associated with reduced disease-free survival, elevated
161 genomic instability, and increased tumor mutation burden in gliomas and pancreatic
162 neuroendocrine tumors (PanNETs)[29–31]. In gliomas, ATRX dysfunction compromises cell-cycle
163 checkpoints, fosters immune evasion, and worsens survival outcomes (Fig 3) [16,32]. Notably,
164 metastatic progression of pheochromocytomas and paragangliomas (PPGLs) have been
165 associated with ATRX mutations, which are among the most frequent gene-level events driving
166 PPGL metastatic potential [17,33,34]. Reflecting these findings, the fifth edition of the WHO
167 classification of Tumours of the Central Nervous System (2021) includes ATRX status as part of
168 the recommended diagnostic workup for gliomas. Recent studies in PanNETs have shown that
169 ATRX inactivation correlates with shorter disease-free intervals, more frequent ALT activation,
170 and increased mortality [30,31,35,36]. Mutations in ATRX, DAXX, and MEN1 (A-D-M mutants)
171 are particularly detrimental, leading to poorer prognoses and lower disease-free survival, with
172 or without ALT phenotype progression. One proposed mechanism involves hypermethylation of
173 CpG islands and subsequent repression of *PDX1*, driving beta pancreatic cells toward an alpha

174 lineage, which is correlated to worse clinical outcomes (Fig 3) [22]. The frequency of ATRX

175 mutations and their correlation to poor prognoses have spurred further exploration of the role

176 of ATRX in PanNETs.

177 **Table 1. Reviews of ATRX in Other Tumours**

Author	Year	Tumour Type	ATRX Status Examined	Effect of ATRX on Outcor
Gonzales-Céspedes (Navarro)[37]	2025	Neuroblastoma	Loss	Poor outcomes: very low surviv
Boehm (Tothill)[38]	2024	Phaeochromocytoma and paraganglioma	Loss	Poor outcomes: ALT, G2M cell cycle c lncRNA dysregulation Good outcomes: increased sensitivity t
Levine (Hawkins)[39]	2024	Pediatric low-grade glioma	Loss	Poor outcomes: aggressive be
O'Neill (Rodriguez-Galindo)[40]	2024	Pediatric adrenocortical carcinoma	Loss	Poor outcomes
Sonnen (Brosen)[30]	2024	PanNENs	Loss	Poor outcomes: telomere dysfunction recurrence rate
Chang (Demirci)[26]	2023	Conjunctival Melanoma	Loss	Poor outcomes: ALT
Hackeng (Dreijerink)[41]	2023	Insulinoma	Loss	Poor outcomes: aggressive be

Haddox (Riedel)[42]	2023	Bone and soft tissue sarcoma	Loss	Good outcomes: increased sensitivi inhibitors
Luchini (Scarpa)[31,43]	2023	PanNENs	Loss	Poor outcomes: ALT, metastasis, tum
Metu (Rahman) [43]	2023	Astrocytoma	Loss	Poor outcomes: ALT Good outcomes: improved pr
Hackeng (Heaphy)[29]	2022	PanNETs	Loss	Poor outcomes: ALT, decreased rec survival
Ren (Li)[28]	2018	Sarcoma	Loss	Poor outcomes: ALT,
Karsy (Colman)[44]	2017	Glioma	Loss	Poor outcomes: ALT, astrocytoma/olig classification

ALT = alternative lengthening of telomeres, PanNENs = pancreatic neuroendocrine neoplasms, PanNETs = pancreatic neuroendocrine tumours

Interestingly, certain tumours with ATRX mutations exhibit heightened sensitivity to immune-mediated therapies (Fig 3). Specifically, ATRX loss can activate IRF transcription factors, leading to increased recruitment of CD4+ and CD3+ T-cells; however, concurrent IDH mutations may obscure this immune sensitization [18]. ATRX disruption has also been observed to enhance the cytotoxic effects of temozolomide (TMZ) treatment in gliomas by reducing ATRX-dependent inhibition of *FADD* transcription. FADD sequesters PARP from DNA, exposing the genome to TMZ and increasing effectiveness of treatment. Loss of ATRX expression is thus

188 associated with increased susceptibility to radiation, chemotherapeutic agents, and
189 immunotherapies, positioning ATRX as a potential therapeutic target [2,20,21].

190 Pituitary neuroendocrine tumours (PitNETs), traditionally known as pituitary adenomas,
191 are common primary intracranial tumours of the adenohypophysis [45]. Like other
192 neuroendocrine tumours, PitNETs are classified based on hormonal secretion. Overproduction
193 and secretion of any adenohypophyseal hormones can cause debilitating effects associated
194 with conditions such as acromegaly and Cushing's disease. Although most clinically apparent
195 PitNETs are benign, approximately 10% exhibit aggressive and invasive behaviour, leading to
196 mass-effect symptoms from compression of adjacent intracranial structures [46,47]. Pituitary
197 neuroendocrine carcinomas (PitNECs), formally pituitary carcinomas (PCs), account for only 0.1-
198 0.5% of PitNET cases [46–50]. Metastases can occur in tumours that appear benign
199 histologically while other tumours that have histological features of aggressiveness can remain
200 isolated to the sellar region. Elevated mitotic activity and Ki-67 index scores are typically
201 associated with aggressive pituitary tumours (APTs) and PCs [48,51]. These tumours often resist
202 conventional surgical and radiotherapeutic interventions, with TMZ only showing moderate and
203 usually transient benefits in less than half of patients [50,52,53]. Survival data for APTs and PCs
204 indicate poor outcomes, with 3- and 5-year survival rates of 59% and 35%, respectively, and
205 median survival times of 17.2 and 11.3 years for patients who are responsive to TMZ [48,54].
206 Alterations in genes regulating chromatin and genome stability – such as *USP8, USP48, BRAF,*
207 *GNAS, and SF3B1* – are frequently associated with worse prognoses and shorter progression-
208 free survival [55,56]. Despite various clinical and pathological markers, no definitive
209 histopathological feature can reliably predict the transition from a benign to an aggressive or

210 metastatic phenotype. Given the growing use of ATRX status as a prognostic marker in other
211 neuroendocrine tumors, it is essential to explore whether ATRX may similarly predict PitNET
212 aggressiveness and outcomes. The heightened susceptibility to mutagenesis and disrupted
213 transcriptional regulation observed in ATRX-deficient gliomas, sarcomas, and other
214 neuroendocrine tumours suggests that similar mechanisms could contribute to the aggressive
215 and proliferative behaviours seen in rare PitNET subtypes.

216 Currently, published data on the incidence of ATRX expression and its clinical
217 significance in neuroendocrine tumours, particularly PitNETs, is limited. The role of ATRX
218 protein expression in the prognosis of PitNETs remains unknown. In this systematic review, we
219 interpret the existing literature on ATRX expression in PitNETs to better describe its relationship
220 with the clinicopathological characteristics and prognosis of PitNET patients.

221 Methods

222 Search strategy

223 This systematic review was conducted following the Preferred Reporting Items for Systematic
224 Reviews and Meta-Analyses (PRISMA) guidelines. The aim was to identify all English published
225 studies on pituitary tumours exhibiting a loss of ATRX expression. The strategy involved
226 searching the PubMed, Embase, and Scopus databases to identify relevant studies published in
227 English from January 1, 2014 to March 1, 2025, using MeSH terms combined with free search
228 terms. A combination of the following keywords was used: ATRX, pituitary, pituitary adenoma,
229 pituitary carcinoma, alpha thalassemia X-linked, ATRX, PitNET. No other restrictions were
230 imposed, and no attempt was made to obtain unpublished results. All references and

231 supplementary data from all selected articles were also considered. The review was not
232 registered, nor was a review protocol prepared. All data collected and analyzed has been
233 reported in the manuscript.

234 Study selection

235 The selection of published material was conducted based on initial screening of titles or
236 abstracts followed by screening of full-text reviews. Manuscripts were considered eligible if they
237 met the following criteria: (i) the study was published in a peer-reviewed medical journal within
238 the last ten years, (ii) the study was published in English, (iii) the study described human case
239 studies involving pituitary tumours/PitNETs and ATRX, and (iv) the study observed a loss of ATRX
240 expression or mutation in the ATRX gene (Fig 4). Studies were omitted from review based on the
241 following exclusion criteria: (i) studies with publication types other than original research
242 articles, such as review articles, editorials, letters, commentaries, and conference abstracts.
243 Duplicate files were removed following export of database search results to Covidence. Risk of
244 bias assessments were evaluated using the Joanna Briggs Institute (JBI) Critical Appraisal
245 Checklist for Studies Reporting Prevalence Data and the JBI Critical Appraisal Checklist for Case
246 Reports [57]. Quality assessment was not performed, and therefore no papers were excluded
247 due to poor quality.

248

249 **Fig 4. Identification and selection of studies via databases.**

250

251 Data extraction and quality assessment

252 Data was extracted from selected articles and included the following characteristics:

253 - Study: year of publication, journal of publication, country, type of study

254 - Sample Data: sample size, tumour type studied, mean age of participants at the time of

255 tumour resection, sex, evaluation strategies,

256 - Study Results and Analysis: tumour classification, ALT status, Ki-67 index, identification

257 of other mutations within tumour sample

258 The analyzed data, including methods and results of each full-length publication, were reviewed

259 to satisfy the selection criteria and assess the quality of the text. No studies were excluded due

260 to poor quality of methods or unsatisfactory results. Results were independently extracted by

261 one author (EW) and assessed by another independent author (FR) to ensure accuracy and

262 inclusion of complete data. Any discrepancies were resolved by discussion.

263 Synthesis of data

264 All relevant patient demographics and tumour data were collected and tabulated in

265 Excel®. Tumours that were referred to as ACTH-secreting tumours, ACTH-omas, or exhibited T-

266 PIT expression were tabulated as corticotrophs. Null cell pituitary tumours were recorded as

267 nonfunctional pituitary adenomas. Similarly, gonadotrophs included tumours categorized by

268 LH/FSH secretion or SF1 expression. One study recorded gonadotrophs as nonfunctional

269 pituitary adenomas and did not specify the number of adenomas recorded [58]. Pit-1 lineage

270 tumours were further categorized into GH-secreting somatotroph and PRL-secreting lactotrophs

271 unless not stated. One study published following the change in pituitary tumour classification

272 also included acidophilic stem cell tumour classification, which was categorized as a lactotroph

273 based on hormone produced [59]. Thyrotrophs included TSH-secreting adenomas and

274 thyrotrophic adenomas. Any tumours that did not fall under these categories were tabulated
275 under "Other Tumour Type," including all plurihormonal tumours, pituitary carcinomas, and
276 pituitary rhabdomyosarcoma. Tumours labelled as metastatic PitNETs were categorized as
277 pituitary carcinomas for analysis. Tumours exhibiting ATRX within the included categories were
278 indicated within square brackets. Analytical techniques and evaluation strategies were indicated
279 in Table 2 while data that was unspecified or not measured was recorded in Table 3. The
280 statistical analysis included Fisher's exact test for associations between tumour recurrence, and
281 other tumour characteristics and ATRX loss. No other statistical or sensitivity analyses were
282 conducted.

283 **Table 2. Characteristics of included publications examining the prevalence of ATRX loss in**
284 **human pituitary neuroendocrine tumours.**

Author	Year	Journal	Country	Type of study	Sample size	Tumour Type	Evaluation Strategy	Loss of ATRX observed? (# if needed)
Casar-Borota (Trouillas)	2017	The American Journal of Surgical Pathology	Denmark	Case report & descriptive cross-sectional study	248	246 PitNET, 2 PC	IHC, NGS	Yes. 1 corticotropic pituitary carcinoma
Guo (Wang)	2018	Frontiers in Oncology	China	Case report & literature review	1	PC	IHC, NGS	Yes
Chen (Dahiya)	2019	Journal of Neuropathy and Experimental Neurology	United States of America	Descriptive cross-sectional study	42	Pediatric PA	IHC	Yes, 3 prolactinomas
Sbiera (Fassnach	2019	Neuro-oncology	Germany	Descriptive cross-	18	PA	WES, Sanger	Yes, 2 corticotroph

t)				sectional study			sequencing	s
Heaphy (Rodriguez)	2020	Modern Pathology	United States of America	Descriptive cross-sectional study	106	PA	IHC, FISH, WES, NGS	Yes, 1 case exhibited a loss of ATRX protein expression but no mutations in ATRX gene
Casar-Borota (Burman)	2021	The Journal of Clinical Endocrinology & Metabolism	Sweden	Descriptive cross-sectional study	47[a]	30 APT, 17 PC[a]	IHC, NGS	Yes, 8 cases (5 carcinomas): 6 corticotrophs (2 carcinomas 1, silent carcinoma, 3 adenomas), 1 lactotroph adenoma, 1 somato-lactotroph carcinoma[a]
Lu (Chen)	2021	Frontiers in Endocrinology	United States of America	Case report	1	Pituitary rhabdomyosarcoma arising from PA	NGS	Yes
Alzoubi (Buttarelli)	2022	Endocrine Pathology	Italy	Descriptive cross-sectional study	36	PA (24 adult recurrent + 12 primary pediatric)	IHC, FISH	Yes, 1 aggressive adult recurrent corticotroph tumour
Lamback (Gadelha)	2024	Journal of Clinical Endocrinology and Metabolism Case Reports	Brazil	Case report	1	PA	IHC	Yes, 1 null cell pituitary adenoma

Terry (Perry)	2024	Endocrine Pathology	United States of America	Descriptive cross-sectional study	13	7 metastatic PitNET, 5 PitNET	IHC, NGS	Yes, 1 silent corticotroph metastatic PitNET

PitNET = pituitary neuroendocrine tumour, PC = pituitary carcinoma, PA = pituitary adenoma, AP = aggressive pituitary tumour, IHC = immunohistochemical analysis, NGS = NextGen sequencing, FISH = fluorescent in-situ telomere hybridization, WES = whole exome sequencing

[a] One patient was omitted from the sample, as it was repeated from Casar-Borota et al. (2017)

Table 3. Demographic and clinical patient data examined in the included publications.

Author (Date)	Average Age	Sex	Recurrent Tumour	Non-recurrent Tumour	Clinically Non-functional	Corticotroph	Somat
Casar-Borota (2017)	Unspecified [39]	Unspecified [F]	Unspecified	Unspecified	152	22	6
Guo (2018)	[55]	[M]	[1]	0	0	0	
Chen (2019)	17.64 [unspecified]	27 F, 15 M [2 F, 1 M]	5	37 [3]	9	9	
Sbiera (2019)	53.7 [52.5]	10 F, 8 M [2 F]	Unspecified	Unspecified	0	18	

Heaphy (2020)	53.4 [unspecified]	65 F, 41 M [unspecified]	18 [unspecified]	88 [unspecified]	83	1	1
Casar-Borota (2021)[c]	45 [45]	14 F, 33 M [2F, 6M]	47 [8]	0	1	10 [3]	
Lu (2021)	[77]	[M]	[1]	0	0	0	
Alzoubi (2022)	Adult: 52.9 Pediatric: 13 [Adult: 60]	Adult: 12 F, 12 M Pediatric: 9 F, 3 M [1 M]	24 adults [1 adult]	12 pediatric	0	6 adults + 2 pediatric [1 adult]	1 a
Lamback (2024)	63	[M]	[1]	0	[1]	0	
Terry (2024)	55 [65]	3 F, 10 M [M]	12 [1]	1	0	2	

292 Values in square brackets indicate samples with ATRX loss reported. ALT-positive = alternative-
293 lengthening of telomeres was present in the tumour sample
294 [a] Studies did not present data on length of follow-up for all subjects. Casar-Borota (2017)
295 described a 6-month follow-up period for one subject. Heaphy (2020) discussed a 2-year follow-
296 up period for one subject. Terry (2024) did not indicate a total length of follow-up but noted
297 that follow-up intervals ranged from 1 to 10 years.
298 [b] Information regarding tumour type and status were incomplete and could not be determined
299 [c] One pituitary carcinoma was excluded as the patient was shared with Casar-Borota (2017)
300 [d] 4 pituitary carcinomas exhibited ATRX loss (2 corticotrophs, 1 silent corticotroph, 1 somato-
301 lactotroph)
302 [e] Two of three specimens were collected from the tumour and evaluated separately for Ki-67
303 labelling index.
304
305

306 Potential for bias and risk of bias assessment

307 Preliminary screening was accomplished by one of the authors (EW) and then
308 reassessed by a second author (FR) according to the defined criteria to ensure that the same
309 data items were collected. The information was extracted from the full text independently by
310 each author. These efforts were directed toward conducting the analysis with minimal bias. Risk
311 of bias and quality assessments were determined using the Joanna Briggs Institute (JBI) Critical
312 Appraisal Checklist for Studies Reporting Prevalence Data (see Table 4) and the JBI Critical
313 Appraisal Checklist For Case Reports (see Table 5) [57].

314 **Table 4: Quality assessment using the Joanna Briggs Institute (JBI) Critical Appraisal Checklist**

315 **for Prevalence Studies**

	Casar-Borota (2017)	Chen (2019)	Sbiera (2019)	Heaphy (2020)	Casar-Borota (2021)	Alzoubi (2022)	Terry (2024)
Was the sample frame appropriate to address the target population?	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Were study participants sampled in an appropriate way?	No	Yes	No	No	Yes	Yes	Yes
Was the sample size adequate?	Unclear	Unclear	Unclear	Unclear	Unclear	Unclear	Unclear
Were the study subjects and the setting described in detail?	No	Yes	Yes	No	Yes	Yes	Yes
Was the data analysis conducted with sufficient coverage of the identified sample?	Unclear	Yes	Yes	No	Yes	Yes	Yes
Were valid methods used for the identification of the condition?	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Was the condition measured in a standard, reliable way?	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Was there appropriate statistical analysis	No	Yes	Yes	Yes	No	Yes	Yes
Was the response rate adequate, and if not, was the low response rate managed appropriately?	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Final Scores	3/8	7/8	6/8	4/8	6/8	7/8	7/8

N/A = Not applicable; the checklist item was not applicable to the study design

Studies with final scores ≥6 are reported as "great" quality. Studies with final scores ≤4 are reported as "poor" quality. Studies with final scores = 5 are reported as "moderate" quality.

Table 5: The Joanna Briggs Institute (JBI) Critical Appraisal Checklist for Risk of Bias for Case Reports that were identified

	Casar-Borota (2017)	Guo (2018)	Lu (2021)	Lamback (2024)
Were patient's demographic characteristics clearly described?	Yes	Yes	Yes	Yes
Was the patient's history clearly described and presented as a timeline?	Yes	Yes	Yes	Yes
Was the current clinical condition of the patient on presentation clearly described?	Yes	Yes	Yes	Yes
Were diagnostic tests or assessment methods and the results clearly described?	Yes	Yes	Yes	Yes
Was the intervention(s) or treatment procedure(s) clearly described?	Yes	Yes	Yes	Yes
Was the post-intervention clinical condition clearly described?	Yes	Yes	No	Yes
Were adverse events (harms) or unanticipated events identified and described?	Unclear	Yes	Unclear	Yes
Does the case report provide takeaway lessons?	Yes	Yes	Yes	Yes
Final Score	7/8	8/8	6/8	8/8

323 Studies with final scores ≥6 are reported as “good” quality. Studies with final scores ≤4 are
324 reported as “poor” quality. Studies with final scores = 5 are reported as “moderate” quality.
325
326

327 Results

328 Description of studies

329 A total of 48 studies were identified from database search after duplicates were
330 removed. Following screening of titles and abstracts, 16 irrelevant studies were excluded. All 32
331 of the remaining studies were retrieved and assessed for inclusion. Of these, 22 publications
332 failed to meet our inclusion criteria and were subsequently excluded. Fourteen studies were
333 excluded due to wrong patient population, of which eleven studies did not examine samples
334 including PitNETs for ATRX expression and mutations, while three studies were excluded due to
335 ATRX mutations occurring outside of the pituitary tumour. Additionally, eight studies were
336 excluded due incorrect study design, as the studies lacked inclusion of novel cases.
337 Consequently, a total of ten publications were included based on the predetermined criteria
338 [58–67].

339 Quality assessments were conducted for the nine studies deemed eligible for inclusion in
340 our review study. Given that the selected descriptive cross-sectional studies were retrospective,
341 analyzing tissue samples and existing medical records, subject response rate was not applicable
342 and thus excluded from the risk of bias assessment. Accordingly, both case reports and
343 descriptive studies were evaluated using an 8-point scale across various checklist parameters

344 [57]. Of the ten human studies that analyzed the prevalence of ATRX loss in PitNETs, three
345 studies presented case reports of a novel case that exhibited ATRX loss, while six were
346 descriptive cross-sectional studies. One study presented both a novel case report and a
347 descriptive cross-sectional study and was evaluated under both quality assessments [58]. Of the
348 seven descriptive studies included in the review, 5/7 (71%) studies received "great" scores (≥6),
349 while 2/7 (29%) studies were categorized as "poor" quality (<4) [58,63]. All four case reports
350 received "great" scores. Nonetheless, because case reports generally focus on single patients
351 and thus have limited generalizability and application, they still represent the weakest form of
352 patient-based evidence (see Tables 4 and 5).

353 Table 2 summarizes the characteristics of the studies examined, including demographic
354 data, sample size, and evaluation strategies. All studies examined were published since 2017. A
355 study was published in each of Canada, China, Denmark, Germany, Italy, Sweden, and Brazil, and
356 four studies published in the USA. Nine studies conducted immunohistochemical analysis to
357 determine ATRX protein presence, while four studies conducted NextGen sequencing to
358 determine the presence and location of ATRX gene mutations. One study did not conduct either
359 immunohistochemical analysis or NextGen sequencing. Instead, the study examined selected
360 tumours using whole-exome sequencing and Sanger sequencing [62]. One study also conducted
361 NextGen sequencing to identify mutations in target genes, but did not report any sequencing
362 results for the tumour lacking ATRX expression [59].

363 As 7/10 (70%) of the studies were conducted on data collected prior to the change in
364 pituitary tumour classification, tumours in these studies were referred to as pituitary adenomas.
365 Five studies examined adult pituitary tumour patients [59,60,62,65,67], while one study

366 examined pediatric pituitary adenoma patients [61]. Three studies included both adult and
367 pediatric pituitary adenoma patients [63,64,66]. One study did not disclose the age range of the
368 patients included in their study [58]. In total, 26 pituitary carcinoma patients were also included
369 from four studies in addition to their pituitary adenoma patients [58–60,64]. Additionally, one
370 study presented a novel case study regarding a pituitary rhabdomyosarcoma arising from a
371 pituitary adenoma that was identified to have a mutation in ATRX [65].

372 Patient data from the studies were summarized in Table 3, including basic patient
373 information and tumour types. A total of 513 tumours were examined across the ten studies
374 included. 246 tumours were clinically non-functional adenomas, 84 somatotroph adenomas, 70
375 corticotroph adenomas, 51 lactotroph adenomas, 15 gonadotroph adenomas, 3 thyrotroph
376 adenomas, and 7 pituitary adenomas present with Pit-1. Several plurihormonal tumours were
377 also included and were described in Table 3. The studies also reported 27 pituitary carcinomas,
378 including 16 classified as corticotroph, 4 as lactotroph, 2 as somatotroph, 2 as null cell, 1 as
379 gonadotroph, and 1 as plurihormonal. It was noted that in 3 of the studies reviewed, data
380 involving age (average), sex, and tumour recurrence was incomplete [58,62,63]. Of the reported
381 ages, the weighted average age of patients was 52. Among the publications that included sex
382 distribution data, there were 148 female patients and 118 male patients. Additionally, 109
383 tumors were identified as recurrent, while 139 were classified as non-recurrent. However, data
384 on follow-up duration were incomplete, with only 5 out of 9 studies providing information on
385 length of follow-up for all subjects. Among these studies, reported follow-up periods ranged
386 from 1.2 to 36 years [60,61,64,65,67].

387 Histopathological data regarding all tumours exhibiting ATRX loss included in this review
388 were summarized in Table 6. Only 20/513 (3.9%) tumours exhibited ATRX loss, of which 12/20
389 (60%) tumours were classified as corticotrophs while 4/20 (20%) were classified as lactotrophs.
390 One study reported a loss of ATRX protein expression in one tumour and partial loss in four
391 other tumours, but did not describe the patient or tumour type of the tumours that exhibited
392 loss of ATRX protein expression [63]. Furthermore, the researchers sequenced only the tumour
393 sample that exhibited full loss of ATRX expression and did not reveal any ATRX genetic
394 abnormalities. They also did not evaluate further the four cases that showed partial loss, and no
395 information was provided regarding the extent of the loss, so they were not classified as ATRX-
396 negative tumors. 17/20 (85%) of the tumours lacking ATRX expression were collected from adult
397 patients, with the remaining three reported as pediatric cases [61].

398 **Table 6. Demographic and histopathological characteristics of tumours exhibiting ATRX.**

	Source	Tumour Classification	Age	Sex	Evaluation	Recurrence Status	ALT Status	Ki-67	Mutations Identified
Tumour 1	Casar-Borota (2017)	Corticotroph pituitary carcinoma	39	F	IHC, NGS	NA	NA	NA	c.134_5217del; p.D45-K2027del[a]
Tumour 2	Guo (2018)	Corticotroph pituitary carcinoma	55	M	IHC, NGS	+	NA	80%	unspecified ATRX mutation
Tumour 3[b]	Chen (2019)	Lactotroph	NA	F	IHC	-	NA	<3%	NA
Tumour 4[b]	Chen (2019)	Lactotroph	NA	F	IHC	-	NA	<3%	NA
Tumour 5[b]	Chen (2019)	Lactotroph	NA	M	IHC	-	NA	>3%	NA
Tumour 6	Sbiera (2019)	Corticotroph	56	F	WES	NA	NA	1-2%	c.622G>C; p.Asp208His
Tumo	Sbiera (2019)	Corticotroph	40	F	WES	NA	NA	5-	g.7577127C>A;

ur 7								6%	p.Glu271Ter
Tumour 8	Heaphy (2020)	NA	NA	NA	IHC, WES, FISH	NA	+	NA	no mutations in ATRX gene
Tumour 9	Casar-Borota (2021)	Corticotroph pituitary carcinoma	45[c]	M	IHC, NGS	+	NA	NA	c.748C>T; p.Arg250Ter
Tumour 10	Casar-Borota (2021)	Corticotroph pituitary carcinoma	45[c]	M	IHC, NGS	+	NA	NA	c.6679delG; p.Asp2227fs c.3583delA; p.Arg1195fs
Tumour 11	Casar-Borota (2021)	Corticotroph pituitary carcinoma	45[c]	F	IHC, NGS	+	NA	NA	c.4048_4049delGG; p.Gly1350fs c.6661G>T; p.Glu2221Ter
Tumour 12	Casar-Borota (2021)	Somato-lactotroph carcinoma	45[c]	M	IHC, NGS	+	NA	NA	c.595_6669del, p.N199-K2233del
Tumour 13	Casar-Borota (2021)	Corticotroph	45[c]	M	IHC, NGS	+	NA	NA	c.2422C>T, p.Arg808Ter
Tumour 14	Casar-Borota (2021)	Corticotroph	45[c]	M	IHC, NGS	+	NA	NA	c.839_840insCATG, p.Asn281Ter
Tumour 15	Casar-Borota (2021)	Silent corticotroph	45[c]	M	IHC, NGS	+	NA	NA	c.5938T>A,c.5939delC, p.Ser1980fs
Tumour 16	Casar-Borota (2021)	Lactotroph APT	45[c]	F	IHC, NGS	+	NA	NA	c.21_6699del, p.E8-K2233del
Tumour 17	Lu (2021)	Pituitary rhabdomyosarcoma arising from pituitary adenoma	77	M	NGS	+	NA	NA	c.5406dup, p.R1803Tfs*7
Tumour 18	Alzoubi (2022)	Corticotroph	60	M	IHC, FISH	+	+	1%	NA
Tumour 19	Lamback (2024)	Nonfunctional null-cell pituitary adenoma	63	M	IHC	+	NA	11%	NA
Tumour 20	Terry (2024)	Corticotroph pituitary carcinoma	65	M	IHC	+	NA	19%	NA

NA = Statistic was not reported or not made available, + = Status associated with column was present, - = Status was evaluated but not present at the time of reporting, IHC =

401 immunohistochemical analysis, NGS = NextGen sequencing, FISH = fluorescent in-situ

402 hybridization, WES = whole exome sequencing

403 [a] Mutation was collected from Casar-Borota et al. (2021)

404 [b] The three lactotrophs in Chen (2019) reported to lack ATRX expression did not specify which

405 of the three cases exhibited a Ki-67 index > 3%.

406 [c] Only average age was reported for the 8 tumours reported to lack ATRX expression. Range of

407 ages was reported as 23-72

408

409

410 Two studies [63,65] reported the number of patients exhibiting the ALT phenotype, of

411 which a total of 14 cases were identified and only 2/14 (14%) tumours exhibited ATRX loss. 5/9

412 studies reported the presence of other mutations within ATRX-negative tumours, of which *TP53*

413 was the most frequently reported mutation (10/18). One study investigated the presence of 20

414 common glioma mutations, including IDH1, IDH2, and ATRX, within the analyzed pituitary

415 tumours, of which 1/248 tumours exhibited a loss of ATRX due to a large deletion within the

416 gene [58]. It was not specified, however, what the other 17 mutations the tumour was screened

417 for or if any other mutations were observed. Ki-67 index was also reported by six studies [59–

418 62,66,67] with different parameters, in which two studies reported proliferation indices greater

419 than 3% as elevated [61,62], whereas another study reported indices greater than 2% as

420 elevated [66]. One study reported an increase in their Ki-67 index by 80% from a prior

421 examination but did not disclose what the absolute values were [60]. One study also reported

422 indices greater than 10% as a marker of high proliferation but did not specify what they

423 determined to be the threshold for an elevated index [67]. Various Ki-67 index thresholds for
424 prognostic significance have been reported in the literature, generally ranging between 1% and
425 10%; hence, all thresholds utilized by the reviewed studies fall within the recognized prognostic
426 range [68]. One study investigated aggressive pituitary adenomas and pituitary carcinomas,
427 which were both characterized by increased proliferation [64].

428 Of the 26 pituitary carcinomas included in the review, 7/26 (27%) exhibited a loss of
429 ATRX expression. 6/7 (86%) carcinomas with ATRX loss were corticotroph in nature while 1/7
430 (14%) presented as a somato-lactotroph. The remaining 19 pituitary carcinomas consisted of
431 10/19 (53%) reported to be corticotroph in nature, 3/19 (16%) as lactotroph in nature, and 2/19
432 (11%) as somatotroph in nature. The average age of pituitary carcinoma patients was between
433 16 and 73, with an average age of 46.1. Unfortunately, average age of carcinomas exhibiting
434 ATRX loss cannot be calculated due to incomplete reporting by one study [64]. All carcinomas
435 exhibited aggressive and transformative properties concomitant with their diagnosis, including
436 elevated proliferative growth, need for repeated surgical procedures, resistance to drug
437 therapies, and development of metastases. None of the studies that included pituitary
438 carcinomas examined the presence of the ALT phenotype. Only two of the studies that
439 presented pituitary carcinoma patients reported Ki-67 indices [59,60]. One study collected Ki-67
440 indices for two samples of the same tumour, recording 5% and 19% scores [59]. The second
441 study reported an increase by 80% from a previous examination but did not provide information
442 regarding the absolute value itself [60].

443 In the analysis of the relationship between ATRX loss and tumour recurrence [Table 7A],
444 tumour hormone secretion [Table 7B], and patient sex [Table 7C], one study was excluded due

445 to incomplete data regarding tumour recurrence, tumour type, and sex of patients with ATRX
446 loss [63]. Two other studies were excluded from tumour recurrence and sex analysis due to
447 incomplete reporting on the two parameters [58,62]. We did not find any significant
448 relationship between loss of ATRX expression and tumour recurrence status [Table 7A]. Sex was
449 also not a significant factor in ATRX expression [Table 7C]. However, tumour type was associated
450 with ATRX expression status. As described in Table 7B, the proportion of ACTH-secreting
451 tumours (corticotroph adenomas and corticotrophic pituitary carcinomas) exhibiting loss of
452 ATRX expression was significantly different from the proportion of other tumours that exhibited
453 ATRX loss ($p < 0.0005$). No other significant associations were observed.

454 **Table 7. Fisher's exact tests comparing ATRX expression status and tumour recurrence (A),**
455 **tumour hormone secretion type (B), and sex of patient (C).**

A	Status of ATRX Expression			
Tumour Recurrence[a]	ATRX Loss	ATRX Intact	Total	p-value
Recurrent	13	78	91	0.078
Non-recurrent	3	47	50	
Total	16	125	141	

B	Status of ATRX Expression			
Tumour Hormone Secretion[b]	ATRX Loss	ATRX Intact	Total	p-value
ACTH	12	75	87	5.52E-05*
Other	7	313	320	
Total	19	388	407	

C	Status of ATRX Expression			
Sex[c]	ATRX Loss	ATRX Intact	Total	p-value
Male	11	72	83	0.146
Female	7	69	76	
Total	18	141	159	

456 * Indicates significant p-value ($p < 0.05$)

457 [a] Casar-Borota et al. (2017), Sbiera et al. (2019), and Heaphy et al. (2020) were excluded due to
458 incomplete data reporting regarding tumour recurrence status
459 [b] Heaphy et al. (2020) was excluded due to incomplete data reporting regarding tumour type.
460 The nonfunctional case presented by Lamback et al. (2024) was included under "Other".
461 [c] Casar-Borota et al. (2017) and Heaphy et al. (2020) were excluded due to incomplete data
462 reporting regarding patient sex
463
464

465 # Discussion

466 In the current study, we reviewed all available literature on ATRX expression in PitNETs.
467 Our analysis revealed a loss of ATRX expression in approximately 3.9% of the 513 cases that
468 were studied. Although ATRX is rarely mutated within PitNETs, patients with functioning
469 PitNETs, especially corticotrophs, are over-represented ($p < 0.0005$).
470 We observed ATRX loss in 4 PitNETs exhibiting the ALT phenotype. However, not all ALT-
471 positive tumours exhibited ATRX loss, suggesting that ATRX loss is not required for the ALT
472 phenotype to progress within the PitNETs studied. ATRX-independent ALT phenotype
473 progression has been observed in other tumour types, supporting this observation [69].
474 However, the limited examination of ALT among included studies limits further examination of
475 this observation. While ATRX loss has been strongly associated with the ALT phenotype in
476 tumour types such as gliomas and pancreatic tumours, we cannot determine a relationship

477 between ATRX function and the progression of the ALT phenotype in PitNETs from currently
478 published data.

479 Given ATRX's critical role in sustaining methylation of repetitive DNA regions, a loss of
480 ATRX expression may lead to errors in DNA replication and transcription during cell division.
481 Coupled with an increased propensity for the development of the ALT phenotype, impaired
482 ATRX function may promote the aberrant proliferative and transformative qualities in PitNETs
483 observed in the analysis. Similar trends have also been identified in PanNETs, where the loss of
484 ATRX/DAXX expression is associated with an increased propensity for proliferative development
485 and poor survival [35]. All studies reviewed here consistently reported an increase in
486 proliferative or transformative properties in tumours lacking ATRX expression. Four studies
487 reported an elevated incidence of ATRX loss in recurrent or aggressive PitNETs, both of which
488 presented with elevated proliferative traits [63,64,66,67]. However, given the multitude of
489 factors, including initial degree of tumour resection and tumour location, the data we collected
490 and analyzed from the publications demonstrated a non-significant trend with ATRX loss and
491 recurrence in PitNETs.

492 Detailed mutation information was available for only 12 of 20 tumours lacking ATRX
493 expression, with 11 cases exhibiting large mutations disrupting multiple domains of the ATRX
494 protein, including frameshifts, early terminations, and extensive deletions. These broad
495 mutations potentially disrupt ATRX-associated pathways, including PRC2- and PML-mediated
496 chromatin regulation processes. Additionally, impaired ATRX-mediated sequestration of MRN
497 complexes and compromised regulation of DNA damage responses may further increase

498 susceptibility to mutations in other tumour suppressor genes or oncogenes, thereby driving
499 aggressive and transformative tumour characteristics in the PitNETs discussed in this review.

500 Loss of ATRX expression was also noted in 27% of the 26 pituitary carcinomas presented
501 across the studies included in this review. Pituitary carcinomas exhibit significant proliferative
502 and transformative properties. The elevated prevalence of ATRX mutations among pituitary
503 carcinomas supports the proposed association between ATRX loss and increased propensity for
504 aggressive and proliferative development of tumours. It was also identified that 86% of the
505 ATRX-negative carcinomas were corticotroph in nature, similar to the trends identified in the
506 data from other ATRX-negative pituitary tumours collected in the review. However, as
507 corticotrophic carcinomas were overrepresented across the samples, making up over 60% of all
508 reported pituitary carcinomas, it is difficult to draw any conclusions from this observation. It is
509 also important to note that in one excluded study, a pituitary carcinoma was found to exhibit
510 ATRX mutations and expression loss in a liver metastasis but not in the original tumour,
511 highlighting the potential for pituitary carcinomas to gain ATRX mutations [70].

512 It is worth noting that mutations in TP53, a well-established tumour suppressor gene,
513 were identified in 50% of tumours exhibiting ATRX loss in the current review. As one of the most
514 frequently mutated genes in cancer, TP53 mutants have a well-established association with
515 proliferative development [71]. Notably, TP53 mutations have been proposed as markers to
516 distinguish neuroendocrine carcinomas from other neuroendocrine neoplasms [72]. Concurrent
517 mutations in TP53 and ATRX have been frequently observed in gliomas and sarcomas, with
518 several studies suggesting the combination of these mutations as prognostic indicators
519 associated with poorer survival outcomes [73,74]. The co-occurrence of TP53 and ATRX

520 mutations presents a significant challenge in isolating and specifically assessing the impact of
521 ATRX loss on the development and prognosis of PitNETs. Given the role of p53 in DNA repair and
522 tumour suppression, mutations in TP53 may increase the propensity for ATRX mutations,
523 thereby promoting proliferative development in pituitary tumours. Future studies may consider
524 investigating ATRX expression in PitNETs and the interplay with TP53 mutations in prognosis of
525 these patients.

526 All tumours exhibiting ATRX mutations and loss discussed in this review were identified
527 using either immunohistochemical analysis (IHC), next-generation sequencing (NGS), or a
528 combination of both. Although no studies have directly compared the effectiveness of NGS and
529 IHC in identifying and assessing ATRX loss in samples, both methods are well-established and
530 widely utilized in the field. The use of IHC for pathological analysis is a standard practice for
531 endocrine and neurological tumour diagnoses as a relatively inexpensive means of detecting
532 changes in protein expression. As ATRX mutations commonly result in truncated proteins, IHC is
533 used to identify loss of ATRX protein expression common in several tumour types [75,76].
534 However, certain ATRX mutations have been found to result in false ATRX positivity during IHC
535 due to positive staining for protein expression despite loss in protein function [77]. As IHC is
536 limited by the antibodies available for detection, unusual mutations can limit the accuracy and
537 effectiveness of such analyses for ATRX mutations. Furthermore, there is also a lack of
538 standardization regarding determination of ATRX loss in tumours like gliomas, where specific
539 thresholds for positive ATRX expression detected by IHC are not well enforced and vary between
540 studies [78]. NGS allows for more comprehensive detection of tumour mutations and can detect
541 multiple mutations across many genes in a single analysis. However, NGS is more costly and

542 time intensive, making it less accessible [79]. NGS may also miss mutations outside of the gene
543 that are impairing ATRX expression. Heaphy et al. identified a loss of ATRX expression in one
544 case by IHC but did not identify any mutations from NGS, suggesting an external mechanism
545 affecting ATRX expression [63]. A combination of IHC and NGS should be applied to provide
546 comprehensive tumour examination. Three studies also used a combination of IHC,
547 fluorescence in-situ hybridization (FISH), and whole exome sequencing (WES) for detection of
548 ATRX mutations [62,63,66]. While FISH offers a cost-effective means of detecting large
549 mutations, it is not sensitive enough to detect small intergenic changes that may affect ATRX
550 expression [79]. WES applies similar practices to NGS, but instead examines a sample's entire
551 exome sequence, leading to far higher costs and time detection [77]. Thus, both FISH and WES
552 are not as effective for frequent detection of ATRX mutations in PitNETs.
553

554 ## Limitations

555 The aim of this study was to review all published research on ATRX mutation and
556 expression in pituitary neuroendocrine tumours. To do so we must accept that we are limited to
557 the type and quality of the published articles from other leading researchers within the field.
558 With regards to our study, we found that the main limitation we identified was the
559 heterogeneity in reporting of results, hampering the ability to perform analyses regarding
560 outcome. For example, one study [63] did not report the tumour type or demographic data of
561 the tumours exhibiting ATRX expression loss, while two other studies [58,62] did not report the
562 average age, sex, and tumour recurrence status of patients in the study. Information regarding
563 duration of follow-up following prognosis and treatment were also incomplete across the study

564 reported in this review. Six studies reported varying follow-up periods between 6 months to 27
565 years, with many limited by patient loss and time between evaluation and publication [59–
566 61,64,65,67]. Two studies also reported on the recurrent tumour characteristics and did not
567 describe any evaluations of ATRX expression in the initial tumour [63,66]. Two studies did not
568 present follow-up reports and data of the pituitary tumours [58,62]. The limited data presented
569 regarding past visits and follow-up periods for patients included in each study hinders
570 investigations on links to aggressive behaviour and recurrence. As a diagnostic marker of
571 aggressive behaviour is recurrence, limited reporting and length of follow-up results may be
572 omitting potential tumours exhibiting ATRX loss.

573 Measurement variability also limited investigations, as the included studies used
574 different parameter thresholds for evaluation. The lack of a standard for declaring ATRX loss and
575 the limited reporting on thresholds used during IHC affect the validity of IHC evaluations of
576 ATRX loss. Furthermore, reporting on proliferative markers like Ki-67 were inconsistent, with
577 varied standards for elevated values. As mentioned earlier, two studies reported elevated Ki-67
578 as values greater than 3% [61,62], while one study reported values greater than 2% as being
579 elevated [66]. The inconsistent reporting of measurements limited any analyses and
580 investigations. Evaluation of reported measures was also limited. While co-occuring mutations
581 were observed and reported among tumours exhibiting ATRX loss, no further analyses were
582 conducted to examine whether any other mutations affected tumour outcomes and
583 measurements. Additionally, the limited research available regarding ATRX expression loss in
584 pituitary tumours further restricted the statistical power of the review, as very few centres were
585 involved in the collection of pituitary tumour samples used in the eight studies examined in the

review. As most patients were collected from neurosurgical centres, patient data may be biased towards more severe and aggressive tumour cases.

Future research

Our literature search revealed that all identified studies were published since 2017, highlighting this as an emerging field that requires further investigation. By comparing larger cohorts of PitNETs with ATRX loss to those with intact ATRX function, along with adequate long-term follow-up on outcomes, we can better understand the clinical significance of ATRX loss in PitNETs. Multivariate analyses of ATRX mutations against other observed mutations like TP53 will assist in isolating the effects of ATRX mutations on PitNET progression. Molecular analyses focused on ATRX-related pathways in ATRX-deficient PitNETs may also reveal deeper insights into the specific consequences of ATRX loss.

Conclusions

Both ATRX loss and mutations are uncommon in PitNETs but when they do occur, they primarily affect functional tumours, particularly those of corticotroph nature. Furthermore, tumours lacking ATRX expression exhibit increased proliferative or transformative characteristics, including a higher incidence of ATRX loss in pituitary carcinomas. Although ATRX is associated with ALT phenotype repression, its loss was not found to exclusively dictate ALT phenotype occurrence, suggesting a more complex relationship between ATRX expression and ALT phenotype activation in PitNETs. This is an emerging area of study, and larger, prospective

606 studies with long follow-up and consistent reporting are crucial to further investigate the
607 implications of ATRX expression loss in PitNETs.
608

609 Data Availability

610 All data for this study were obtained from publicly available sources cited in the manuscript.
611 Extracted and summarized data supporting the findings of this study are included within the
612 manuscript and Supporting Information files. No new data was generated.
613

614 Acknowledgment

615 Authors are grateful to the Lloyd Carr-Harris Foundation for their continuous support.
616

617 References

618 1. Yuan K, Tang Y, Ding Z, Peng L, Zeng J, Wu H, et al. Mutant ATRX: pathogenesis of ATRX
619 syndrome and cancer. Front Mol Biosci. 2024;11. doi:10.3389/fmolb.2024.1434398
620 2. Aguilera P, López-Contreras AJ. ATRX, a guardian of chromatin. Trends in Genetics.
621 2023;39: 505–519. doi:10.1016/j.tig.2023.02.009
622 3. Goncalves T, Bhatnagar H, Cunniffe S, Gibbons RJ, Rose AM, Clynes D. Phosphorylation of
623 'SDT-like' motifs in ATRX mediates its interaction with the MRN complex and is important
624 for ALT pathway suppression. Open Biol. 2024;14. doi:10.1098/rsob.240205

625 4. Corpet A, Kleijwegt C, Roubille S, Juillard F, Jacquet K, Texier P, et al. PML nuclear bodies
626 and chromatin dynamics: catch me if you can! Nucleic Acids Res. 2020;48: 11890–11912.
627 doi:10.1093/nar/gkaa828
628 5. Valenzuela M, Amato R, Sgura A, Antoccia A, Berardinelli F. The Multiple Facets of ATRX
629 Protein. Cancers (Basel). 2021;13: 2211. doi:10.3390/cancers13092211
630 6. Xue Y, Gibbons R, Yan Z, Yang D, McDowell TL, Sechi S, et al. The ATRX syndrome protein
631 forms a chromatin-remodeling complex with Daxx and localizes in promyelocytic
632 leukemia nuclear bodies. Proceedings of the National Academy of Sciences. 2003;100:
633 10635–10640. doi:10.1073/pnas.1937626100
634 7. Voon HPJ, Wong LH. New players in heterochromatin silencing: histone variant H3.3 and
635 the ATRX/DAXX chaperone. Nucleic Acids Res. 2016;44: 1496–1501.
636 doi:10.1093/nar/gkw012
637 8. Iwase S, Xiang B, Ghosh S, Ren T, Lewis PW, Cochrane JC, et al. ATRX ADD domain links an
638 atypical histone methylation recognition mechanism to human mental-retardation
639 syndrome. Nat Struct Mol Biol. 2011;18: 769–76. doi:10.1038/nsmb.2062
640 9. Eustermann S, Yang J-C, Law MJ, Amos R, Chapman LM, Jelinska C, et al. Combinatorial
641 readout of histone H3 modifications specifies localization of ATRX to heterochromatin.
642 Nat Struct Mol Biol. 2011;18: 777–782. doi:10.1038/nsmb.2070
643 10. Gibbons RJ, Picketts DJ, Villard L, Higgs DR. Mutations in a putative global transcriptional
644 regulator cause X-linked mental retardation with α-thalassemia (ATR-X syndrome). Cell.
645 1995;80: 837–845. doi:10.1016/0092-8674(95)90287-2

646 11. Gibbons RJ, Pellagatti A, Garrick D, Wood WG, Malik N, Ayyub H, et al. Identification of
647 acquired somatic mutations in the gene encoding chromatin-remodeling factor ATRX in
648 the α-thalassemia myelodysplasia syndrome (ATMDS). Nat Genet. 2003;34: 446–449.
649 doi:10.1038/ng1213
650 12. Nguyen PC, Tiong IS, Westerman DA, Blombery P. A novel *ATRX* variant with splicing
651 consequences in myelodysplastic syndrome with acquired alpha thalassaemia. Br J
652 Haematol. 2023;200. doi:10.1111/bjh.18525
653 13. Roake CM, Artandi SE. Keeping It in the Family: ATRX Loss Promotes Persistent Sister
654 Telomere Cohesion in ALT Cancer Cells. Cancer Cell. 2015;28: 277–279.
655 doi:10.1016/j.ccell.2015.08.005
656 14. Scott WA, Dhanji EZ, Dyakov BJA, Dreseris ES, Asa JS, Grange LJ, et al. ATRX proximal
657 protein associations boast roles beyond histone deposition. PLoS Genet. 2021;17:
658 e1009909. doi:10.1371/journal.pgen.1009909
659 15. Teng Y-C, Sundaresan A, O'Hara R, Gant VU, Li M, Martire S, et al. ATRX promotes
660 heterochromatin formation to protect cells from G-quadruplex DNA-mediated stress. Nat
661 Commun. 2021;12: 3887. doi:10.1038/s41467-021-24206-5
662 16. Nandakumar P, Mansouri A, Das S. The Role of ATRX in Glioma Biology. Front Oncol.
663 2017;7. doi:10.3389/fonc.2017.00236
664 17. Tothill R, Flynn A, Pattison A, Balachander S, Boehm E, Bowen B, et al. Multi-omic analysis
665 of SDHB-deficient pheochromocytomas and paragangliomas identifies metastasis and
666 treatment-related molecular profiles. 2024. doi:10.21203/rs.3.rs-4410500/v1

667 18. Hariharan S, Whitfield BT, Pirozzi CJ, Waitkus MS, Brown MC, Bowie ML, et al. Interplay
668 between ATRX and IDH1 mutations governs innate immune responses in diffuse gliomas.
669 Nat Commun. 2024;15: 730. doi:10.1038/s41467-024-44932-w
670 19. Darmusey L, Pérot G, Thébault N, Le Guellec S, Desplat N, Gaston L, et al. ATRX Alteration
671 Contributes to Tumor Growth and Immune Escape in Pleomorphic Sarcomas. Cancers
672 (Basel). 2021;13: 2151. doi:10.3390/cancers13092151
673 20. Han B, Meng X, Wu P, Li Z, Li S, Zhang Y, et al. ATRX/EZH2 complex epigenetically regulates
674 FADD/PARP1 axis, contributing to TMZ resistance in glioma. Theranostics. 2020;10: 3351–
675 3365. doi:10.7150/thno.41219
676 21. Xie Y, Wang H, Wang S, Feng Y, Feng Y, Fan S, et al. Clinicopathological Significance of ATRX
677 Expression in Nasopharyngeal Carcinoma Patients: A Retrospective Study. J Cancer.
678 2021;12: 6931–6936. doi:10.7150/jca.63333
679 22. Chan CS, Laddha S V., Lewis PW, Koletsky MS, Robzyk K, Da Silva E, et al. ATRX, DAXX or
680 MEN1 mutant pancreatic neuroendocrine tumors are a distinct alpha-cell signature
681 subgroup. Nat Commun. 2018;9: 4158. doi:10.1038/s41467-018-06498-2
682 23. Chen Y-T, Jiang M-M, Leynes C, Adeyeye M, Majano CF, Ibrahim B, et al. ATRX silences
683 Cartpt expression in osteoblastic cells during skeletal development. Journal of Clinical
684 Investigation. 2025;135. doi:10.1172/JCI163587
685 24. Clynes D, Jelinska C, Xella B, Ayyub H, Scott C, Mitson M, et al. Suppression of the
686 alternative lengthening of telomere pathway by the chromatin remodelling factor ATRX.
687 Nat Commun. 2015;6: 7538. doi:10.1038/ncomms8538

688 25. Raghunandan M, Yeo JE, Walter R, Saito K, Harvey AJ, Ittershagen S, et al. Functional cross
689 talk between the Fanconi anemia and ATRX/DAXX histone chaperone pathways promotes
690 replication fork recovery. Hum Mol Genet. 2020;29: 1083–1095.
691 doi:10.1093/hmg/ddz250
692 26. Chang E, Demirci H, Demirci FY. Genetic Aspects of Conjunctival Melanoma: A Review.
693 Genes (Basel). 2023;14: 1668. doi:10.3390/genes14091668
694 27. Lally SE, Milman T, Orloff M, Dalvin LA, Eberhart CG, Heaphy CM, et al. Mutational
695 Landscape and Outcomes of Conjunctival Melanoma in 101 Patients. Ophthalmology.
696 2022;129: 679–693. doi:10.1016/j.ophtha.2022.01.016
697 28. Ren X, Tu C, Tang Z, Ma R, Li Z. Alternative lengthening of telomeres phenotype and loss
698 of ATRX expression in sarcomas (Review). Oncol Lett. 2018. doi:10.3892/ol.2018.8318
699 29. Hackeng WM, Assi HA, Westerbeke FHM, Brosens LAA, Heaphy CM. Prognostic and
700 Predictive Biomarkers for Pancreatic Neuroendocrine Tumors. Surg Pathol Clin. 2022;15:
701 541–554. doi:10.1016/j.path.2022.05.007
702 30. Sonnen AF-P, Verschuur AVD, Brosens LAA. Diagnostic and prognostic biomarkers for
703 pancreatic neuroendocrine neoplasms. Die Pathologie. 2024;45: 74–82.
704 doi:10.1007/s00292-024-01393-8
705 31. Luchini C, Scarpa A. Neoplastic Progression in Neuroendocrine Neoplasms of the
706 Pancreas. Arch Pathol Lab Med. 2024;148: 975–979. doi:10.5858/arpa.2022-0417-RA
707 32. Hu C, Wang K, Damon C, Fu Y, Ma T, Kratz L, et al. ATRX loss promotes immunosuppressive
708 mechanisms in IDH1 mutant glioma. Neuro Oncol. 2022;24: 888–900.
709 doi:10.1093/neuonc/noab292

710 33. Calsina B, Piñeiro-Yáñez E, Martínez-Montes ÁM, Caleiras E, Fernández-Sanromán Á,
711 Monteagudo M, et al. Genomic and immune landscape Of metastatic
712 pheochromocytoma and paraganglioma. Nat Commun. 2023;14: 1122.
713 doi:10.1038/s41467-023-36769-6
714 34. Job S, Draskovic I, Burnichon N, Buffet A, Cros J, Lépine C, et al. Telomerase Activation and
715 ATRX Mutations Are Independent Risk Factors for Metastatic Pheochromocytoma and
716 Paraganglioma. Clinical Cancer Research. 2019;25: 760–770. doi:10.1158/1078-0432.CCR-
717 18-0139
718 35. Singhi AD, Liu T-C, Roncaioli JL, Cao D, Zeh HJ, Zureikat AH, et al. Alternative Lengthening
719 of Telomeres and Loss of DAXX/ATRX Expression Predicts Metastatic Disease and Poor
720 Survival in Patients with Pancreatic Neuroendocrine Tumors. Clinical Cancer Research.
721 2017;23: 600–609. doi:10.1158/1078-0432.CCR-16-1113
722 36. Hackeng WM, Brosens LAA, Kim JY, O'Sullivan R, Sung Y-N, Liu T-C, et al. Non-functional
723 pancreatic neuroendocrine tumours: ATRX/DAXX and alternative lengthening of
724 telomeres (ALT) are prognostically independent from ARX/PDX1 expression and tumour
725 size. Gut. 2022;71: 961–973. doi:10.1136/gutjnl-2020-322595
726 37. Gonzales-Céspedes G, Navarro S. High-risk neuroblastoma: ATRX and TERT as prognostic
727 markers and therapeutic targets. Review and update on the topic. Revista Española de
728 Patología. 2025;58: 100790. doi:10.1016/j.patol.2024.100790
729 38. Boehm E, Gill AJ, Clifton-Bligh R, Tothill RW. Recent progress in molecular classification of
730 phaeochromocytoma and paraganglioma. Best Pract Res Clin Endocrinol Metab. 2024;38:
731 101939. doi:10.1016/j.beem.2024.101939

732 39. Levine AB, Hawkins CE. Molecular markers for pediatric low-grade glioma. Child's
733 Nervous System. 2024;40: 3223–3228. doi:10.1007/s00381-024-06639-7
734 40. O'Neill A, Ribeiro R, Pinto E, Clay M, Zambetti G, Orr B, et al. Pediatric Adrenocortical
735 Carcinoma: The Nuts and Bolts of Diagnosis and Treatment and Avenues for Future
736 Discovery. Cancer Manag Res. 2024;Volume 16: 1141–1153. doi:10.2147/CMAR.S348725
737 41. Hackeng WM, Brosens LAA, Dreijerink KMA. Aggressive versus indolent insulinomas: new
738 clinicopathological insights. Endocr Relat Cancer. 2023;30. doi:10.1530/ERC-22-0321
739 42. Haddox CL, Riedel RF. Emerging predictive biomarkers in the management of bone and
740 soft tissue sarcomas. Expert Rev Anticancer Ther. 2023;23: 495–502.
741 doi:10.1080/14737140.2023.2200169
742 43. Nahar Metu CL, Sutihar SK, Sohel M, Zohora F, Hasan A, Miah MdT, et al. Unraveling the
743 signaling mechanism behind astrocytoma and possible therapeutics strategies: A
744 comprehensive review. Cancer Rep. 2023;6. doi:10.1002/cnr2.1889
745 44. Karsy M, Guan J, Cohen AL, Jensen RL, Colman H. New Molecular Considerations for
746 Glioma: IDH, ATRX, BRAF, TERT, H3 K27M. Curr Neurol Neurosci Rep. 2017;17: 19.
747 doi:10.1007/s11910-017-0722-5
748 45. Asa SL, Mete O, Perry A, Osamura RY. Overview of the 2022 WHO Classification of
749 Pituitary Tumors. Endocr Pathol. 2022;33: 6–26. doi:10.1007/s12022-022-09703-7
750 46. Russ S, Anastasopoulou C, Shafiq I. Pituitary Adenoma. StatPearls; 2024.
751 47. Nishioka H. Aggressive pituitary tumors (PitNETs). Endocr J. 2023;70: EJ23-0007.
752 doi:10.1507/endocrj.EJ23-0007

753 48. Burman P, Trouillas J, Losa M, McCormack A, Petersenn S, Popovic V, et al. Aggressive
754 pituitary tumours and carcinomas, characteristics and management of 171 patients. Eur J
755 Endocrinol. 2022;187: 593–605. doi:10.1530/EJE-22-0440
756 49. Kasuki L, Raverot G. Definition and diagnosis of aggressive pituitary tumors. Rev Endocr
757 Metab Disord. 2020;21: 203–208. doi:10.1007/s11154-019-09531-x
758 50. Raverot G, Burman P, McCormack A, Heaney A, Petersenn S, Popovic V, et al. European
759 Society of Endocrinology Clinical Practice Guidelines for the management of aggressive
760 pituitary tumours and carcinomas. Eur J Endocrinol. 2018;178: G1–G24. doi:10.1530/EJE-
761 17-0796
762 51. Lasolle H, Vasiljevic A, Jouanneau E, Ilie MD, Raverot G. Aggressive corticotroph tumors
763 and carcinomas. J Neuroendocrinol. 2022;34. doi:10.1111/jne.13169
764 52. Raverot G, Ilie MD, Lasolle H, Amodru V, Trouillas J, Castinetti F, et al. Aggressive pituitary
765 tumours and pituitary carcinomas. Nat Rev Endocrinol. 2021;17: 671–684.
766 doi:10.1038/s41574-021-00550-w
767 53. McCormack A, Dekkers OM, Petersenn S, Popovic V, Trouillas J, Raverot G, et al.
768 Treatment of aggressive pituitary tumours and carcinomas: results of a European Society
769 of Endocrinology (ESE) survey 2016. Eur J Endocrinol. 2018;178: 265–276.
770 doi:10.1530/EJE-17-0933
771 54. Santos-Pinheiro F, Penas-Prado M, Kamiya-Matsuoka C, Waguespack SG, Mahajan A,
772 Brown PD, et al. Treatment and long-term outcomes in pituitary carcinoma: a cohort
773 study. Eur J Endocrinol. 2019;181: 397–407. doi:10.1530/EJE-18-0795

774 55. Reincke M, Sbiera S, Hayakawa A, Theodoropoulou M, Osswald A, Beuschlein F, et al.
775 Mutations in the deubiquitinase gene USP8 cause Cushing's disease. Nat Genet. 2015;47:
776 31–38. doi:10.1038/ng.3166
777 56. Spada A, Mantovani G, Lania AG, Treppiedi D, Mangili F, Catalano R, et al. Pituitary
778 Tumors: Genetic and Molecular Factors Underlying Pathogenesis and Clinical Behavior.
779 Neuroendocrinology. 2022;112: 15–33. doi:10.1159/000514862
780 57. Aromataris E, Lockwood C, Porritt K, Pilla B, Jordan Z. JBI Manual for Evidence Synthesis.
781 Aromataris E, Lockwood C, Porritt K, Pilla B, Jordan Z, editors. JBI; 2024.
782 doi:10.46658/JBIMES-24-01
783 58. Casar-Borota O, Botling J, Granberg D, Stigare J, Wikström J, Boldt HB, et al. Serotonin,
784 ATRX, and DAXX Expression in Pituitary Adenomas: Markers in the Differential Diagnosis
785 of Neuroendocrine Tumors of the Sellar Region. Am J Surg Pathol. 2017;41: 1238–1246.
786 doi:10.1097/PAS.0000000000000908
787 59. Terry M, Nguyen MP, Tang V, Guney E, Bharani KL, Dahiya S, et al. High-Grade Progression,
788 Sarcomatous Transformation, and/or Metastasis of Pituitary Neuroendocrine Neoplasms
789 (PitNENs): The UCSF Experience. Endocr Pathol. 2024. doi:10.1007/s12022-024-09829-w
790 60. Guo F, Wang G, Wang F, Xu D, Liu X. Identification of Novel Genes Involved in the
791 Pathogenesis of an ACTH-Secreting Pituitary Carcinoma: A Case Report and Literature
792 Review. Front Oncol. 2018;8: 510. doi:10.3389/fonc.2018.00510
793 61. Chen J, Schmidt RE, Dahiya S. Pituitary Adenoma in Pediatric and Adolescent Populations.
794 J Neuropathol Exp Neurol. 2019;78: 626–632. doi:10.1093/jnen/nlz040

795 62. Sbiera S, Perez-Rivas LG, Taranets L, Weigand I, Flitsch J, Graf E, et al. Driver mutations in
796 USP8 wild-type Cushing's disease. Neuro Oncol. 2019;21: 1273–1283.
797 doi:10.1093/neuonc/noz109
798 63. Heaphy CM, Bi WL, Coy S, Davis C, Gallia GL, Santagata S, et al. Telomere length
799 alterations and ATRX/DAXX loss in pituitary adenomas. Mod Pathol. 2020;33: 1475–1481.
800 doi:10.1038/s41379-020-0523-2
801 64. Casar-Borota O, Boldt HB, Engström BE, Andersen MS, Baussart B, Bengtsson D, et al.
802 Corticotroph Aggressive Pituitary Tumors and Carcinomas Frequently Harbor ATRX
803 Mutations. J Clin Endocrinol Metab. 2021;106: 1183–1194. doi:10.1210/clinem/dgaa749
804 65. Lu J, Chen L. Molecular Profile of a Pituitary Rhabdomyosarcoma Arising From a Pituitary
805 Macroadenoma: A Case Report. Front Endocrinol (Lausanne). 2021;12: 752361.
806 doi:10.3389/fendo.2021.752361
807 66. Alzoubi H, Minasi S, Gianno F, Antonelli M, Belardinilli F, Giangaspero F, et al. Alternative
808 Lengthening of Telomeres (ALT) and Telomerase Reverse Transcriptase Promoter
809 Methylation in Recurrent Adult and Primary Pediatric Pituitary Neuroendocrine Tumors.
810 Endocr Pathol. 2022;33: 494–505. doi:10.1007/s12022-021-09702-0
811 67. Lamback E, Miranda RL, Ventura N, Chimelli L, Gadelha MR. Loss of ATRX Protein
812 Expression in an Aggressive Null Cell Pituitary Tumor. JCEM Case Reports. 2024;2.
813 doi:10.1210/jcemcr/luae143
814 68. Chudasama P, Mughal SS, Sanders MA, Hübschmann D, Chung I, Deeg KI, et al. Integrative
815 genomic and transcriptomic analysis of leiomyosarcoma. Nat Commun. 2018;9.
816 doi:10.1038/s41467-017-02602-0

817 69. Sumislawski P, Rotermund R, Klose S, Lautenbach A, Wefers AK, Soltwedel C, et al. ACTH-
818 secreting pituitary carcinoma with TP53, NF1, ATRX and PTEN mutations Case report and
819 review of the literature. Endocrine. 2022;76: 228–236. doi:10.1007/s12020-021-02954-0
820 70. Olivier M, Hollstein M, Hainaut P. TP53 Mutations in Human Cancers: Origins,
821 Consequences, and Clinical Use. Cold Spring Harb Perspect Biol. 2010;2: a001008–
822 a001008. doi:10.1101/cshperspect.a001008
823 71. Sun BL, Ding H, Sun X. Histopathologic and genetic distinction of well-differentiated grade
824 3 neuroendocrine tumor versus poorly-differentiated neuroendocrine carcinoma in high-
825 grade neuroendocrine neoplasms. Am J Clin Pathol. 2025. doi:10.1093/ajcp/aqaf013
826 72. Crowell C, Mata-Mbemba D, Bennett J, Matheson K, Mackley M, Perreault S, et al.
827 Systematic review of diffuse hemispheric glioma, H3 G34-mutant: Outcomes and
828 associated clinical factors. Neurooncol Adv. 2022;4: vdac133.
829 doi:10.1093/noajnl/vdac133
830 73. Dermawan JK, Chiang S, Singer S, Jadeja B, Hensley ML, Tap WD, et al. Developing Novel
831 Genomic Risk Stratification Models in Soft Tissue and Uterine Leiomyosarcoma. Clinical
832 Cancer Research. 2024;30: 2260–2271. doi:10.1158/1078-0432.CCR-24-0148
833 74. Heaphy CM, de Wilde RF, Jiao Y, Klein AP, Edil BH, Shi C, et al. Altered Telomeres in Tumors
834 with *ATRX* and *DAXX* Mutations. Science (1979). 2011;333: 425–425.
835 doi:10.1126/science.1207313
836 75. Wiestler B, Capper D, Holland-Letz T, Korshunov A, von Deimling A, Pfister SM, et al. ATRX
837 loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH

838 mutant astrocytic tumors with better prognosis. Acta Neuropathol. 2013;126: 443–451.
839 doi:10.1007/s00401-013-1156-z
840 76. Reuss DE, Sahm F, Schrimpf D, Wiestler B, Capper D, Koelsche C, et al. ATRX and IDH1-
841 R132H immunohistochemistry with subsequent copy number analysis and IDH
842 sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma,
843 oligodendroglioma and glioblastoma. Acta Neuropathol. 2015;129: 133–146.
844 doi:10.1007/s00401-014-1370-3
845 77. Tanboon J, Williams EA, Louis DN. The Diagnostic Use of Immunohistochemical
846 Surrogates for Signature Molecular Genetic Alterations in Gliomas. J Neuropathol Exp
847 Neurol. 2016;75: 4–18. doi:10.1093/jnen/nlv009
848 78. Scheie D, Kufaishi HHA, Broholm H, Lund EL, de Stricker K, Melchior LC, et al. Biomarkers
849 in tumors of the central nervous system – a review. APMIS. 2019;127: 265–287.
850 doi:10.1111/apm.12916
851

852 # Supporting Information

853 **Figure S1. PRISMA 2020 Checklist**


GATA
PHD
HP1α
SDT
DAXX
nMECP2
ADD
EZH2
SNF2 ATPase/Helicase


ATRX
PML-NB
DAXX
ATRX
HP1α
PRC2
EZH2
ATRX
Xist
DAXX
ATRX
MRN
ATRX
DNAP
ATRX
G4
Heterochromatin
↓ Transcription
X- chromosome
Telomeres
↑ Transcription
R-loop
ATRX
lncRNA
TERRA
Telomere
PCH
DRR
↑ α-globin
↑ tankyrase
Telomere cohesion
T-SCEs
RNAPII
↑ Transcription
TERRA
H3
H3.3
macroH2A
H3K9me3
H3K27me3
Mechanism is unclear


ATRX Mutation
α-THALASSEMIA
macroH2A
ATRX
α-globin
Germline
ATR-X Syndrome
ADD
ATPase
PanNETs
MEN1
DAXX
ATRX
CpG islands
PDX1
A-D-M
EARLY DEVELOPMENT*
ATRX
CART
Osteoclast Activity
Trabecular Bone
DRG2
RPRM
S
G2
G2M
G1
M
G2M
Checkpoint
Regulation
+IDH1(R132H)
BRD3/4
IL-33
CXCL
IL-6
CSF2
IL-8
PD-1
CD8+
M2
T-Cell Exhaustion
Macrophage
Recruitment
Immune
Escape
GLIOMA
dsRNA
RIG1
MDA-5
STAT1
ISG15
IRF3
IRF7
CD4+
Type 1 IFN
CD3+
Cytokines
Innate
Immunity
Sensitization
EZH2
ATRX
FADD
FADD
PARP
PARP
TMZ
TMZ
Sensitivity
PML-NB
APB
T-SCE
Telomeric
C-circles
TERRA
G4
R-Loop
ALT


Identification
Studies from databases/registers (n = 137)
PubMed (n = 87)
Scopus (n = 50)
Embase (n = 0)
References removed before screening (n = 89)
Duplicate records removed (n = 89)
Screening
Studies screened (n = 48)
Studies excluded (n = 16)
Studies sought for retrieval (n = 32)
Studies not retrieved (n = 0)
Studies assessed for eligibility (n = 32)
Studies excluded (n = 22)
Wrong patient population (n = 14)
Wrong study design (n = 8)
Included
Studies included in review (n = 10)